The main factors causing the high prevalence of liver cancer caused by the absence of specific symptoms at early stages of liver cancer 
development which has resulted in most patients are diagnosed at an advanced stage. Background of this, research was done by focusing on increasing life expectancy, maintaining and improving quality of life of patients.
Research and find Sorafenib systemic therapy, therapy that uses drugs as an attempt to suppress tumor growth by inhibiting enzymes of two types of kinases (enzymes) needed for the development of cancer cells and blood supply.
According to data the World Health Organization (WHO) to the present, liver cancer ranked 3rd in the world cause of cancer-related deaths. Recorded 625 thousand cases diagnosed each year, where the mortality rate reached 396 thousand. Generally, people with liver cancer are men with an age range 40 to 50 years.
Hospital oncologists Dharmais, Agus S Waspodo Liver Cancer in socializing with the idea of Bayer Health Care in Jakarta, Friday (19/11) said, Sorafenib is a drug that could provide signals to the cell nucleus. This means, a protein that makes cancer grow and can not be produced.
"Not all cancers can be treated only by resection techniques (amputation) or ablation (burn), because most cancer cells had already spread," he said.
"The question is, who's willing to cut him. It is a constraint, too. In addition, like other transplants, liver transplants may therefore difficult process," he added.
From a clinical trial involving 602 liver cancer patients, patients who undergo the program by taking this drug can survive an average of 10.7 months, while the other group received placebo on average to survive up to 7.9 months.
So far, based on clinical trials SHARP (Sorafenib HCC Assessment randomized Procotol), sorafenib may bring benefits for patients with cancer, especially cancer of the liver with various levels of the stadium. "Despite successful clinical trials only increase life expectancy to be 3 months, but have great meaning for defending one's survival," he said.
When asked whether these drugs have side effects like other therapies, Agus explained, people do not have to worry about the side effects caused. According to him, the side effects caused by Sorafenib still manageable. Everything was certainly no side effects. Live see, how the level of side effects, whether to run or not, "he said,
"Unfortunately, people tend to see the side effects rather than benefits. Like for example, when undergoing kemauterapi, people tend to worry about his hair than the benefits," he said.
development which has resulted in most patients are diagnosed at an advanced stage. Background of this, research was done by focusing on increasing life expectancy, maintaining and improving quality of life of patients.Research and find Sorafenib systemic therapy, therapy that uses drugs as an attempt to suppress tumor growth by inhibiting enzymes of two types of kinases (enzymes) needed for the development of cancer cells and blood supply.
According to data the World Health Organization (WHO) to the present, liver cancer ranked 3rd in the world cause of cancer-related deaths. Recorded 625 thousand cases diagnosed each year, where the mortality rate reached 396 thousand. Generally, people with liver cancer are men with an age range 40 to 50 years.
Hospital oncologists Dharmais, Agus S Waspodo Liver Cancer in socializing with the idea of Bayer Health Care in Jakarta, Friday (19/11) said, Sorafenib is a drug that could provide signals to the cell nucleus. This means, a protein that makes cancer grow and can not be produced.
"Not all cancers can be treated only by resection techniques (amputation) or ablation (burn), because most cancer cells had already spread," he said.
"The question is, who's willing to cut him. It is a constraint, too. In addition, like other transplants, liver transplants may therefore difficult process," he added.
From a clinical trial involving 602 liver cancer patients, patients who undergo the program by taking this drug can survive an average of 10.7 months, while the other group received placebo on average to survive up to 7.9 months.
So far, based on clinical trials SHARP (Sorafenib HCC Assessment randomized Procotol), sorafenib may bring benefits for patients with cancer, especially cancer of the liver with various levels of the stadium. "Despite successful clinical trials only increase life expectancy to be 3 months, but have great meaning for defending one's survival," he said.
When asked whether these drugs have side effects like other therapies, Agus explained, people do not have to worry about the side effects caused. According to him, the side effects caused by Sorafenib still manageable. Everything was certainly no side effects. Live see, how the level of side effects, whether to run or not, "he said,
"Unfortunately, people tend to see the side effects rather than benefits. Like for example, when undergoing kemauterapi, people tend to worry about his hair than the benefits," he said.
Tidak ada komentar:
Posting Komentar